Mark Elliott Boulding Ptc Therapeutics, Inc. (PTCT) insider trading activity

Mark Elliott Boulding is EXEC. VP AND CLO of PTC THERAPEUTICS, INC.. Currently has a direct ownership of 103,901 shares of PTCT, which is worth approximately $5.74 Million. The most recent transaction as insider was on Feb 20, 2025, when has been sold 1,614 shares (Common Stock) at a price of $50.12 per share, resulting in proceeds of $80,893. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 104K

12.46% 3M change

12.46% 12M change

Total Value Held $5.74 Million

Mark Elliott Boulding Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 20 2025	SELL Open market or private sale	$80,893 $50.12 p/Share	1,614 Reduced 1.53%	103,901 Common Stock
Feb 19 2025	SELL Open market or private sale	$66,783 $50.1 p/Share	1,333 Reduced 1.25%	105,515 Common Stock
Jan 08 2025	SELL Open market or private sale	$88,911 $44.5 p/Share	1,998 Reduced 1.84%	106,848 Common Stock
Jan 07 2025	SELL Open market or private sale	$69,959 $45.34 p/Share	1,543 Reduced 1.4%	108,846 Common Stock
Jan 03 2025	BUY Grant, award, or other acquisition	-	18,000 Added 14.02%	110,389 Common Stock
Dec 03 2024	SELL Open market or private sale	$551,478 $53.5 p/Share	10,308 Reduced 10.04%	92,389 Common Stock
Dec 03 2024	BUY Exercise of conversion of derivative security	$340,370 $33.02 p/Share	10,308 Added 9.85%	94,377 Common Stock
Dec 02 2024	SELL Open market or private sale	$4,469,176 $52.21 p/Share	85,600 Reduced 48.09%	92,389 Common Stock
Dec 02 2024	BUY Exercise of conversion of derivative security	$4,365,600 $51.0 p/Share	85,600 Added 32.72%	176,029 Common Stock
Feb 15 2024	BUY Grant, award, or other acquisition	-	21,200 Added 18.66%	92,389 Common Stock
Jan 30 2024	SELL Open market or private sale	$21,636 $27.25 p/Share	794 Reduced 1.1%	71,189 Common Stock
Jan 09 2024	SELL Open market or private sale	$56,221 $29.01 p/Share	1,938 Reduced 2.62%	71,983 Common Stock
Jan 08 2024	SELL Open market or private sale	$41,728 $28.64 p/Share	1,457 Reduced 1.93%	73,921 Common Stock
Apr 17 2023	SELL Open market or private sale	$3,184,080 $51.42 p/Share	61,923 Reduced 45.1%	75,378 Common Stock
Apr 17 2023	BUY Exercise of conversion of derivative security	$1,910,943 $30.86 p/Share	61,923 Added 31.6%	134,009 Common Stock
Jan 31 2023	SELL Open market or private sale	$37,051 $45.63 p/Share	812 Reduced 1.07%	75,378 Common Stock
Jan 11 2023	SELL Open market or private sale	$21,958 $44.36 p/Share	495 Reduced 0.65%	76,190 Common Stock
Jan 10 2023	SELL Open market or private sale	$25,328 $42.93 p/Share	590 Reduced 0.76%	76,685 Common Stock
Jan 09 2023	SELL Open market or private sale	$34,786 $41.66 p/Share	835 Reduced 1.07%	77,275 Common Stock
Jan 05 2023	BUY Grant, award, or other acquisition	-	17,000 Added 17.87%	78,110 Common Stock
Oct 18 2022	SELL Open market or private sale	$16,520 $55.25 p/Share	299 Reduced 0.49%	61,110 Common Stock
Oct 18 2022	BUY Exercise of conversion of derivative security	$9,227 $30.86 p/Share	299 Added 0.48%	61,399 Common Stock
Oct 17 2022	SELL Open market or private sale	$363,110 $55.0 p/Share	6,602 Reduced 9.75%	61,110 Common Stock
Oct 17 2022	BUY Exercise of conversion of derivative security	$203,738 $30.86 p/Share	6,602 Added 8.91%	67,512 Common Stock
Sep 20 2022	SELL Open market or private sale	$64,680 $55.0 p/Share	1,176 Reduced 1.89%	61,110 Common Stock

MEB

Mark Elliott Boulding

EXEC. VP AND CLO

South Plainfield, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PTCT shares.

Notify only if

Value

Insider Trading

Get notified when an Ptc Therapeutics, Inc. insider buys or sells PTCT shares.

Notify only if

Operation

Value

Type

News

Receive news related to PTC THERAPEUTICS, INC.

Track Activities on PTCT

Account